Liver transplantation has become an immense success; nevertheless, far more recipients
are registered on waiting lists than there are available donor livers for transplantation. High …

Non-alcoholic fatty liver disease encompasses a spectrum of liver diseases, including
simple steatosis, steatohepatitis, liver fibrosis and cirrhosis and hepatocellular carcinoma …

Strategies to increase the use of steatotic donor livers are required to tackle the mortality on
the transplant waiting list. We aimed to test the efficacy of pharmacological enhancement of …

Metabolic dysfunction-associated steatohepatitis (MASH, previously termed non-alcoholic
steatohepatitis (NASH)), is a major complication of obesity that promotes fatty liver disease …

Normothermic perfusion provides a means to rescue steatotic liver grafts, including by
pharmacological defatting. In this study, we tested the potential of new drug combinations to …

Although prevalent, nonalcoholic fatty liver disease is not currently treated effectively with
medicines. Initially, using wild-type and genome-edited clones of the human hepatocyte cell …

Macrosteatotic livers exhibit elevated intrahepatic triglyceride (TG) levels in the form of large
lipid droplets (LDs), reduced adenosine triphosphate (ATP) levels, and elevated reactive …

Liver steatosis is emerging as a major cause of chronic liver disease worldwide, mainly due
to the increasing rate of obesity, type 2 diabetes, and metabolic syndrome. Because of the …

Non-alcoholic fatty liver disease is a huge cause of chronic liver failure around the world.
This condition has become more prevalent as rates of metabolic syndrome, type 2 diabetes …

Introduction Pharmacological defatting of rat hepatocytes and hepatoma cell lines suggests
that the same method could be used to ameliorate macrovesicular steatosis in moderate to …